Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon

Minerva Cardioangiologica

Volumn 47, Issue 5, 1999, Pages 137-143

  Bartolone, S ^a   Trifiletti, A ^a   De Nuzzo, G ^a   Scamardi, R ^a   Larosa, D ^a   Sottilotta, G ^a   Raffa, A ^a   Barbera, N ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Alprostadil sleroderma; Systemic Raynaud's phenomenon

Indexed keywords

PLACEBO; PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; BLOOD FLOW; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; FEMALE; HUMAN; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SCLERODERMA; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

ALPROSTADIL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MIDDLE AGED; PLACEBOS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 0032781027     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Heberden Papers. Systemic Sclerosis (Scleroderma). Ann Rheum Dis 1991;50(Suppl 4):854-61.
2. Bashar K, Matucci-Cerinic M. Raynaud's phenomenon and scleroderma. Arthritis Rheum 1995;38(1):1-4.
3. Blann AD, Illingworth K, Jayson MIV. Mechanism of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 1993;20(8):1325-8.
4. Raynaud M. On local asphixic and symmetrical gangrene of the extremities and new researches in the nature and treatment of local asphixia of the extremities. Selected monographs. London: Sydenham Society, 1988;121.
5. Gallone L. Patologia chirurgica. V edizione. Milano, 1986;1:217-222.
6. Goyle KB, Dormandi YA. Abnormal blood viscosity in Raynaud's phenomenon. Lancet 1976;2:1317.
7. Blunt RJ, George AS, Hurlow RA, Strachan CJL, Stuart J. Iperviscosity and thrombotic changes and secondary Raynaud's syndrom. Br J Haematol 1980;45:657.
8. Lewis T. Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation in the fingers. A variety of Raynaud's disease. Heart 1929;15:7.
9. Smith CD, Mc Kendry RJR. Controlled trials of nifedipine in the treatment of Raynaud's phenomenon. Lancet 1982;2:1299.
10. Sorkin EM, Clissold SP, Brogden RN. Nifedipine: a review of pharmacodinamic and pharmacocinetic properties and its therapeutic efficacy in ischaemichart disease, hypertension and related cardiovascular disorders. Drugs 1985;30:182.
11. Rademaker M, Cooke ED, Almond NE. Confronto fra iloprost per infusione endovenosa e nifedipina per via orale nel trattamento del fenomeno di Raynaud in pazienti affetti da sclerosi sistemica: uno studio randomizzato in doppio cieco. Edizione Italiana. Br J 1990;12:53.
12. Windstone EL, Pariser KM, Miller KB, Salem DM, Creager MA. Nifedipine as a therapeutic modality for Rynaud's phenomenon. Arthritis Rheum 1983;26:1177.
13. Kahan A. Nifedipine in the treatment of Raynaud's syndrome. Ann Intern Med 1981;94:546.
14. Rademaker M, Thomas RHM, Provost G, Beacham JA, Cook ED, Kirby JD. Prolonged increased in digital blood flow following iloprost infusion in patients with systemic sclerosis. Postgrad Med J 1987;63:617.
15. Mchugh MJ, Csuka M, Watson H, Belcher G, Arnadi A, Ring EFJ, Black CM, Maddison PJ. Infusion of iloprost, a prostacycline analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988;47:43.
16. Yardumian DA, Isemberg DA, Rustin M, Belcher G, Snaith ML, Dowd PM et al. Successful treatment of Raynaud's syndrom with iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 1988;7:220.
17. Tortley HY, Madhok R, Capell HA, Brouwer RM, Maddison PJ, Black CM et al. A double bind, randomized, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue disease. Ann Rheum Dis 1991;50:800.
18. Steinberg H, Medvedv OS, Luft FC, Unger T. Effect of prostacycline derivate (iloprost) on regional blood flow, sympatic nerve activity, and baroreceptor reflex in the conscious rat. J Cardiovasc Pharmacol 1988;11:84.
19. Bursch W, Schulte-Hermann R. Cytoprotective effect of iloprost against liver cell dead induced by carbon tetrachloride or brombenzene. In: Gryglewsky RJ, Stock G, editors. Prostacyclin and its stable analogue iloprost. Berlin, Heidelberg New York: Springer-Verlag, 1986:257.
20. Allen A, O'Reilly MJG. Treatment of severe Raynaud's phenomenon with prostaglandin E1. Irish Med J 1981;150:190-1.
21. Clifford PC, Martin MFR, Sheddon EJ. Treatment of vasospastic disease with prostaglandin E1. Br Med J 1980;281:1031-4.
22. Martin MFR, Dowd PM, Ring EFG. Prostaglandin F.1 infusions for vascular insufficiency in progressive systemic sclerosis. Ann Rheum Dis 1981;40:350-4.
23. Martin MFR, Tooke JE. Effects of prostaglandine E1 on microvascular haemodynamics in progressive systemic sclerosis. Br Med J 1982;285:1688-90.
24. Mizushima Y, Shiokawa Y, Homma M. A multicenter double blind controlled study of lipoPGE1, PGE1, incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders. J Rheumatol 1987;14:97-101.
25. Mohrland JS, Porter JM, Smith EA. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome. Ann Rheum Dis 1985;44:754-60.
26. Pardy BJ, Hoare MC, Eastcott HHG. Prostaglandin E1 in severe Raynaud's phenomenon. Surgery 1987;92: 953-65.
27. Langevitz P, Buskila D, Lee P, Urowitz MB. Treatment of refractary skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions. J Rheumatol 1989;16(11):14335.
28. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;30:581-90
29. Ippolito F, Di Carlo A. Lo studio del microcircolo. Sicurezza e protezione n.10. Gennaio-Aprile 1996.